Ganesh Vaheisvaran is a corporate associate in the Tokyo office of Morrison Foerster. His practice focuses on public and private mergers, acquisitions, joint ventures, and other corporate transactions for clients in a wide variety of industries.
Ganesh received his LL.B. from the University of Sydney Law School. During his time in law school, he studied for one semester at Yonsei University (Korea). Ganesh received his B.Comm. (Finance) from the University of Sydney Business School. During his time in business school, he studied for one semester at Keio University (Japan). He is now a part-time lecturer at the Keio University Law School.
Prior to joining Morrison Foerster, Ganesh worked at a leading magic circle law firm in its London and Tokyo offices.
Ganesh is admitted to practice law in England and Wales and is qualified as a gaikokuho-jimu-bengoshi in Japan.
Ganesh is recommended by The Legal 500 Asia Pacific for Corporate and M&A category as “a very reliable and hard working senior associate who undertakes his work diligently and efficiently”. He has also been recognized by The Best Lawyers in Japan in its “Ones to Watch” category for Corporate and M&A Law.
Bain Capital’s acquisition of Mitsubishi Tanabe Pharma
Represented Bain Capital on its ¥510 billion acquisition of Mitsubishi Tanabe Pharma from Mitsubishi Chemical Group.
Tokyo Gas’s investment in Philippine LNG terminal
Represented Tokyo Gas on its investment in, and joint venture with First Gen for, an LNG import and regasification terminal project in Batangas province, Philippines.
Renesas’s India partnership for OSAT facility
Represented Renesas on the establishment of its Indian joint venture with CG Power and Industrial Solutions and Stars Microelectronics for the establishment of a greenfield outsourced semiconductor assembly and testing (OSAT) facility in India.
CMIC HOLDINGS’ strategic capital alliance with Blackstone
Represented CMIC HOLDINGS on its strategic capital alliance in respect of CMIC Co., Ltd., Japan’s leading clinical research organization (CRO), with funds managed by Blackstone.
Tokyo Gas’s investment in and exit from a portfolio of renewable energy projects in Mexico
Represented Tokyo Gas on its investment with ENGIE in a portfolio of renewable energy projects in Mexico and its subsequent exit from such portfolio.
Kong’s Japan partnership
Represented Kong on the establishment of its Japanese joint venture with Japan Cloud for the commercialization of Kong products in Japan.
SoftBank’s investment in AMEA Power
Represented SoftBank Group on its $75 million investment in AMEA Power.
Sumitomo’s sale of the San Cristóbal mine
Represented Sumitomo on its sale of the San Cristóbal mine in Bolivia to San Cristóbal Mining Inc. At the time, the mine was one of the largest silver, zinc, and lead mines in the world.
First Solar’s sale of its Japan development and O&M platform
Represented First Solar on its sale of its Japan development business, operation & maintenance business and solar projects to PAG.
Pacific Impact Development’s Southeast Asia-focused renewable energy platform
Represented Pacific Impact Development on its formation of a Southeast Asia-focused renewable energy platform with SUSI Partners.
A consortium of foreign sponsors in the sale of solar projects in Japan
Represented a consortium of foreign sponsors on its sale of (1) a portfolio of solar projects in Japan to Enfinity Global and (2) a 30.9 MW solar power project located in Fukushima Prefecture, Japan.
Sumitomo’s investment in Light Rail Manila Corporation
Represented Sumitomo Corporation on its investment in Light Rail Manila Corporation, the operator of the Manila Light Rail Transit System Line 1.
A foreign sponsor’s sale of solar projects in Japan
Represented a foreign sponsor on its sale of a portfolio of three solar power projects located in Gifu and Tochigi Prefectures, Japan, with an aggregate capacity of 67.62 MW.
X-Elio’s sale of solar projects in Japan
Represented X-Elio on its sale of (1) a “ready-to-build” solar project in Miyagi, Japan to Vena Energy and (2) the Mine solar project in Yamaguchi, Japan to Sonnedix.
iCON Infrastructure’s sale of Firmus Energy
Represented iCON Infrastructure on its sale of Firmus Energy to Equitix Investment
GCA’s acquisition by Houlihan Lokey
Represented GCA on its ¥65.9 billion acquisition by Houlihan Lokey.
AIG’s Brexit reorganization
Represented AIG on the reorganization (involving a court-approved insurance business transfer scheme and cross-border merger) of its European operations in preparation for Brexit.
Saudi British Bank’s merger with Alawwal Bank
Represented HSBC on the $5 billion merger of its associate company, the Saudi British Bank, with Alawwal Bank.
LSEG’s proposed merger with Deutsche Börse
Represented London Stock Exchange Group on its proposed £21 billion merger with Deutsche Börse.
Warburg Pincus’s acquisition of Emerging Markets Payments
Represented Warburg Pincus on its $340 million acquisition (through Network International) of Emerging Markets Payments.
Zurich Insurance’s potential acquisition of RSA Insurance
Represented Zurich Insurance Group on its potential £5.6 billion acquisition of RSA Insurance.
MUFG’s investment in Grab
Represented MUFG on its $706 million investment in Grab.
Palantir’s Japan partnerships
Represented Palantir Technologies on (1) its formation with Sompo Holdings of a joint venture company, Palantir Technologies Japan KK, to market and deploy Palantir’s data analytics software and services to customers in Japan and (2) its strategic alliance with Fujitsu through which Fujitsu will sell its digital transformation services to complement Palantir’s software platforms.
SoftBank’s investment in Ola Electric Mobility
Represented SoftBank Group on its $250 million investment in Ola Electric Mobility.
TelecityGroup’s acquisition by Equinix
Represented TelecityGroup on its £2.6 billion acquisition by Equinix.
Lenovo’s acquisition of stake in Lenovo NEC Holdings
Represented Lenovo on its $195 million acquisition of part of NEC’s stake in Lenovo NEC Holdings.
Ono Pharmaceutical’s acquisition of Itolizumab
Represented Ono Pharmaceutical on its up-to-¥21.5 billion acquisition of the rights to Itolizumab from Equillium.